A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis
Atul Khandekar
Advertisement
Atul Khandekar is COO of SymphonyTech Biologics
Articles by Atul Khandekar
Advertisement
Latest Updated Articles
- A Systematic Evaluation of Risks and Mitigation Strategies for Convalescent Plasma Therapy for COVID-19
Published: February 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access
5
